JP2021534750A5 - - Google Patents
Info
- Publication number
- JP2021534750A5 JP2021534750A5 JP2021509199A JP2021509199A JP2021534750A5 JP 2021534750 A5 JP2021534750 A5 JP 2021534750A5 JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021509199 A JP2021509199 A JP 2021509199A JP 2021534750 A5 JP2021534750 A5 JP 2021534750A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence ids
- sequence
- cancer
- antigen
- ids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862720015P | 2018-08-20 | 2018-08-20 | |
| US62/720,015 | 2018-08-20 | ||
| PCT/CN2019/101659 WO2020038379A1 (en) | 2018-08-20 | 2019-08-20 | Novel cancer immunotherapy antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534750A JP2021534750A (ja) | 2021-12-16 |
| JP2021534750A5 true JP2021534750A5 (cg-RX-API-DMAC7.html) | 2022-08-22 |
| JP7488534B2 JP7488534B2 (ja) | 2024-05-22 |
Family
ID=69591356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509199A Active JP7488534B2 (ja) | 2018-08-20 | 2019-08-20 | 新規ながん免疫療法抗体組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12391758B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3841126A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7488534B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210046725A (cg-RX-API-DMAC7.html) |
| CN (3) | CN116063519B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019324388A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021003182A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3110138A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021002077A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202101757QA (cg-RX-API-DMAC7.html) |
| TW (1) | TW202016150A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020038379A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250223361A1 (en) * | 2022-04-01 | 2025-07-10 | Mabtree Biologics Ag | Human antibody or antigen binding fragment thereof specific against pd-l1 to enhance t-cell function |
| CN118930652B (zh) * | 2024-07-29 | 2025-03-11 | 北京肿瘤医院(北京大学肿瘤医院) | 一种免疫检查点pd-l2靶向单链抗体及放射性核素标记物与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101704734B1 (ko) * | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CA2615460A1 (en) * | 2005-08-08 | 2007-02-15 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| BR112014012819B1 (pt) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| EP2863947B1 (en) * | 2012-06-21 | 2018-03-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CA3175360C (en) * | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| TW201639891A (zh) * | 2015-03-10 | 2016-11-16 | 索倫多醫療公司 | 結合psma之抗體治療劑 |
| CN114853891A (zh) | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN106432501B (zh) * | 2015-08-06 | 2021-07-30 | 基石药业 | 新型抗pd-l1抗体 |
| ES2986360T3 (es) * | 2016-01-29 | 2024-11-11 | Yuhan Corp | Proteínas de unión a antígeno que se unen a PD-L1 |
| US10059769B2 (en) * | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
| CN106496327B (zh) * | 2016-11-18 | 2019-01-15 | 昆山百尔泰生物科技有限公司 | 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体 |
| CN108239149B (zh) * | 2016-12-25 | 2021-03-05 | 南京传奇生物科技有限公司 | 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-l1抗体 |
| CN107973854B (zh) * | 2017-12-11 | 2021-05-04 | 苏州银河生物医药有限公司 | Pdl1单克隆抗体及其应用 |
| CA3117853A1 (en) * | 2018-10-29 | 2020-05-07 | 1Globe Biomedical Co., Ltd. | Novel rationally designed protein compositions |
-
2019
- 2019-08-20 WO PCT/CN2019/101659 patent/WO2020038379A1/en not_active Ceased
- 2019-08-20 CA CA3110138A patent/CA3110138A1/en active Pending
- 2019-08-20 SG SG11202101757QA patent/SG11202101757QA/en unknown
- 2019-08-20 KR KR1020217008130A patent/KR20210046725A/ko not_active Abandoned
- 2019-08-20 TW TW108129705A patent/TW202016150A/zh unknown
- 2019-08-20 MX MX2021002077A patent/MX2021002077A/es unknown
- 2019-08-20 CN CN202211332831.XA patent/CN116063519B/zh active Active
- 2019-08-20 CN CN202310026623.5A patent/CN116410320B/zh active Active
- 2019-08-20 EP EP19853152.7A patent/EP3841126A4/en active Pending
- 2019-08-20 JP JP2021509199A patent/JP7488534B2/ja active Active
- 2019-08-20 AU AU2019324388A patent/AU2019324388A1/en not_active Abandoned
- 2019-08-20 BR BR112021003182-0A patent/BR112021003182A2/pt not_active IP Right Cessation
- 2019-08-20 CN CN201980054723.0A patent/CN112839963B/zh active Active
- 2019-08-20 US US17/270,034 patent/US12391758B2/en active Active